Search IDXG
INTERPACE BIOSCIENCES, INC.
OTC, OTC · CIK 1054102
Last close6.03
Daily change-0.36 (-5.71%)
10 Years gain-61.13%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
IDXG · STANDARD
SIC 3841 · Surgical & Medical Instruments & Apparatus · Fiscal year end 1231
Fundamental
50.1Momentum
0.0Acceleration
0.0Confidence
90.0Annual Revenue16
Quarterly Revenue53
Annual CFO16
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth4.9 / 25
Quality16.1 / 25
Capital Efficiency11.6 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
Gross margin compression · MEDIUMGross margin compressed by 2.2392 percentage points.
Operating margin compression · MEDIUMOperating margin compressed by 11.2435 percentage points.
Key Metrics
Revenue Growth TTM-21.46%OK
Revenue CAGR 3Y6.75%OK
Gross Margin61.61%OK
Operating Margin5.87%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC17.09%OK
Incremental Operating Margin 3Y41.79%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y0.03%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $38.73M | $24.13M | $4.08M | $5.83M | $5.48M | 62.31% | 10.55% | 14.14% | 32.81% | 27.7M |
| 2025 FY Dec 31, 2024 | $46.93M | $29.93M | $8.11M | $4.65M | $3.77M | 63.77% | 17.28% | 8.03% | n/a | 15.73M |
| 2024 FY Dec 31, 2023 | $40.04M | $25.06M | $3.96M | $3.79M | $3.32M | 62.58% | 9.88% | 8.29% | n/a | 4.36M |
| 2023 FY Dec 31, 2022 | $31.84M | $18.23M | -$3.62M | -$7.69M | -$8.01M | 57.26% | -11.36% | -25.17% | n/a | 4.24M |
| 2022 FY Dec 31, 2021 | $33.12M | $18.80M | -$6.34M | -$8.72M | -$9.07M | 56.78% | -19.13% | -27.4% | n/a | 4.14M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $36.15M | sum latest 4 fiscal quarters Revenue | OK | 0001493152-26-036895, 0001493152-25-021928 |
| Revenue Growth TTM | -21.46% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001493152-26-036895, 0001493152-25-021928 |
| Revenue CAGR 3Y | 6.75% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001493152-26-013646 |
| Revenue CAGR 5Y | 3.63% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001493152-26-013646 |
| Gross Profit CAGR 3Y | 9.79% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001493152-26-013646 |
| Operating Income Growth | -73.07% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001493152-26-036895, 0001493152-25-021928 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 61.61% | Gross Profit / Revenue | OK | 0001493152-26-036895, 0001493152-25-021928 |
| Operating Margin | 5.87% | Operating Income / Revenue | OK | 0001493152-26-036895, 0001493152-25-021928 |
| ROIC | 17.09% | NOPAT / Average Invested Capital | OK | 0001493152-26-036895, 0001493152-25-021928 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001493152-26-036895 |
| Current Ratio | 2.22x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $1.30 | Revenue / Diluted Shares | OK | 0001493152-26-036895, 0001493152-25-021928 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |